ethyl 4-isothiocyanatobutanoate has been researched along with Ovarian Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bodo, J; Chovancova, J; Hunakova, L; Sedlak, J | 1 |
| Bodo, J; Duraj, J; Hunakova, L; Jakubikova, J; Kasparkova, J; Kvasnicka, P; Sedlak, J | 1 |
2 other study(ies) available for ethyl 4-isothiocyanatobutanoate and Ovarian Neoplasms
| Article | Year |
|---|---|
Enhanced sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to the combination of cisplatin and synthetic isothiocyanate ethyl 4-isothiocyanatobutanoate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butyrates; Cell Cycle; Cell Proliferation; Cisplatin; Drug Synergism; Female; Flow Cytometry; Humans; Isothiocyanates; Ovarian Neoplasms | 2005 |
Sensitisation for cisplatin-induced apoptosis by isothiocyanate E-4IB leads to signalling pathways alterations.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Butyrates; Caspase 3; Cell Cycle Proteins; Cell Proliferation; Cisplatin; Drug Synergism; Drug Therapy, Combination; Female; Glutathione; Humans; Isothiocyanates; Membrane Potentials; Mitochondria; Ovarian Neoplasms; Protein Kinases; Signal Transduction; Tumor Cells, Cultured | 2006 |